Overview

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

Status:
RECRUITING

Trial end date:
2028-09-20

Target enrollment:

Participant gender:

Summary

GEMINI-PeriOp GC study will assess the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of novel agents or novel combinations as perioperative treatment in participants with locally advanced resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma who have not received previous treatment for the disease.

Phase:

PHASE2

Details

Lead Sponsor:

AstraZeneca

Collaborator:

Parexel

Treatments:

Capecitabine
Fluorouracil
trastuzumab deruxtecan